Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02872025
Title Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Laura Esserman
Indications

ductal carcinoma in situ

Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.